MedTrace Logo

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

NCT03184584 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-11-03

No results posted yet for this study

Summary

Phase 2, open-label, single-arm, multi-centre study evaluating the long term safety and tolerability of PBI-4050 in subjects with Alström Syndrome who have completed a preceding ProMetic-sponsored Alström Syndrome study with PBI-4050.

Conditions

  • Alström Syndrome

Interventions

DRUG

PBI-4050

Four 200 mg capsules (800 mg total) administered orally, once daily

Sponsors & Collaborators

  • Liminal BioSciences Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2020-05-08
Completion
2020-05-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03184584 on ClinicalTrials.gov